English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

In the era of cytokine therapy, 2 prospective randomized clinical trials (RCTs) demonstrated significantly more superior overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients receiving cytoreductive nephrectomy followed by interferon-α (IFN-α) than of those treated with IFN-α alone (1,2); therefore, it has been recognized as a standard therapeutic approach for mRCC patients to perform cytoreductive nephrectomy prior to the introduction of systemic therapy.

Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe?